Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BIBF 1120 Long-term Open-label Extension in Idiopathic Pulmonary Fibrosis
CTR20132119Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Aug 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of nintedanib in idiopathic pulmonary fibrosis (IPF), sponsored by Boehringer Ingelheim. Started Aug 2014; status: completed.
02
Drugs
nintedanib
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on CTR20132119.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20132119.